Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab in combination with carboplatin and docetaxel (TCH) - 21 days for reimbursement as a treamtent option for the adjuvant treatment of HER2 positive early breast cancer.

This is written in the approval document as:

Adjuvant treatment HER2 positive early breast cancer

Citation

DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days, 2023, version number 8, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/258.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab